| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PT Diagnos Laboratorium Utama Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp234.00 |
| 52 Week High | Rp436.00 |
| 52 Week Low | Rp188.00 |
| Beta | 0.44 |
| 11 Month Change | -14.60% |
| 3 Month Change | 20.62% |
| 1 Year Change | -12.03% |
| 33 Year Change | -71.46% |
| 5 Year Change | n/a |
| Change since IPO | -13.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| DGNS | ID Healthcare | ID Market | |
|---|---|---|---|
| 7D | -6.4% | -1.9% | -1.3% |
| 1Y | -12.0% | 21.4% | 12.8% |
Return vs Industry: DGNS underperformed the ID Healthcare industry which returned 24% over the past year.
Return vs Market: DGNS underperformed the ID Market which returned 12.2% over the past year.
Price Volatility
| DGNS volatility | |
|---|---|
| DGNS Average Weekly Movement | 11.2% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: DGNS's share price has been volatile over the past 3 months compared to the ID market.
Volatility Over Time: DGNS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of ID stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 91 | Mesha Sini | diagnos.co.id |
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want to have a child, oncology tests, drug sensitivity, DNAandMe, and others. It also offers homecare health services for hemoglobin, ferritin, retilulosit, hematologi rutin, SARS-COV-2 omicron screening molecular test, and PCR SARS-COV-2 H+1 B2C; and SARS-CoV-2 screening services.
PT Diagnos Laboratorium Utama Tbk Fundamentals Summary
| DGNS fundamental statistics | |
|---|---|
| Market cap | Rp292.50b |
| Earnings (TTM) | -Rp4.76b |
| Revenue (TTM) | Rp155.53b |
1.9x
P/S Ratio-61.5x
P/E RatioIs DGNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGNS income statement (TTM) | |
|---|---|
| Revenue | Rp155.53b |
| Cost of Revenue | Rp88.78b |
| Gross Profit | Rp66.75b |
| Other Expenses | Rp71.51b |
| Earnings | -Rp4.76b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.81 |
| Gross Margin | 42.92% |
| Net Profit Margin | -3.06% |
| Debt/Equity Ratio | 17.8% |
How did DGNS perform over the long term?
See historical performance and comparison